Vertex Pharmaceuticals Incorporated research snapshot
VRTX AI stock analysis currently reads Vertex Pharmaceuticals as a high-quality biotechnology company with a dominant cystic fibrosis franchise, expanding launches in CASGEVY and JOURNAVX, a broad renal, pain, diabetes, and rare disease pipeline, and a new $10 billion Crinetics acquisition that adds endocrinology exposure. Vertex reported Q1 2026 revenue of $2.99 billion, up 8%, GAAP net income of $1.03 billion, non-GAAP EPS of $4.47, and cash plus marketable securities of about $13.0 billion. At the July 8, 2026 intraday reference of $511.30 and 253.81 million shares outstanding, the verified market cap was about $129.77 billion. This VRTX AI stock forecast is scenario-based, not a precise price prediction, and should be used as an informational research tool, not investment advice.
Current price
$511.30 intraday reference on July 8, 2026
Market cap
$129.77 billion equity value
AI score
74 / 100
Rating
High-quality large-cap biotech with CF franchise durability, pipeline optionality, and acquisition integration risk
Trend status
Strong long-term trend, mixed short-term pullback after the Crinetics acquisition announcement
Data cutoff (updated weekly)
July 8, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Vertex monetizes rare disease biology through high-margin approved medicines, with CF still the cash engine and newer franchises in gene therapy, acute pain, renal disease, and endocrine disease intended to diversify growth. | High |
| Moat | The moat comes from CFTR modulator leadership, patents, biology-specific discovery capability, regulatory experience, payer and physician trust, and a pipeline built around causal human biology. | Medium-high |
| Management | CEO Reshma Kewalramani has pushed Vertex beyond CF into CASGEVY, JOURNAVX, povetacicept, and now Crinetics, but capital allocation must prove that large pipeline and M&A spending can earn attractive returns. | Medium-high |
| Financial trend | Q1 2026 revenue rose 8% to $2.99 billion, GAAP net income rose to $1.03 billion, non-GAAP operating income reached $1.31 billion, and cash plus marketable securities increased to about $13.0 billion. | High |
| Valuation | At $511.30, VRTX screened near 30.3x trailing EPS, 6.7x book value, 35.0x free cash flow per share, 10.6x sales per share, and a 2.9% free cash flow yield in the audited model. | High |
| Technical trend | The stock is above the 50-day and 200-day moving averages, but below the 5-day moving average after a short pullback, making the setup constructive but not a clean breakout entry. | Medium |
| Risk level | Key risks are CF concentration, payer and drug pricing pressure, clinical and FDA setbacks, slow CASGEVY or JOURNAVX adoption, manufacturing issues, Crinetics integration, and valuation compression. | Medium-high |
| AI confidence | Descriptive data confidence is high because Vertex provides current official releases and third-party market data is available for cross-checks. | High data confidence |
| Investment certainty | VRTX looks like a high-quality biotech compounder, but not a low-risk bargain because the current price still depends on durable CF cash flow and multiple non-CF programs converting into durable revenue. | Medium |
VRTX AI stock forecast
The VRTX AI stock forecast uses the July 8, 2026 intraday reference of $511.30, TTM EPS of $16.86, and a three-year earnings multiple framework. The financial_rigor.py model produced a bearish area near $369, a base area near $611, and a bullish area near $779 before dividends, future repurchases, Crinetics closing effects, pipeline outcomes, or multiple changes. These are scenario ranges, not promises.
$750 to $800
More likely if CF revenue remains durable, ALYFTREK expands the franchise, CASGEVY and JOURNAVX adoption improves, povetacicept advances on schedule, Crinetics adds credible endocrine growth, and investors continue paying around the low-30s earnings multiple.
$590 to $625
More likely if EPS grows around 9% annually, 2026 revenue lands near the $12.95 billion to $13.1 billion guidance range, non-CF products begin to matter without disrupting margins, and VRTX trades near 28x forward earnings.
$350 to $390
More likely if CF growth slows faster than expected, non-CF launches disappoint, drug pricing pressure rises, Crinetics fails to justify the acquisition premium, trial data disappoint, or the market compresses VRTX toward about 20x earnings.
VRTX AI technical analysis
VRTX AI technical analysis is constructive but pullback-sensitive as of the July 8, 2026 data cutoff. StockAnalysis listed an intraday price of $511.30, while Investing.com showed daily technical indicators in a Strong Buy position, RSI near 45.6, MACD positive, a 5-day moving average near $517.67, a 50-day moving average near $508.31, and a 200-day moving average near $464.37. ChartMill described the long-term trend as up and the short-term trend as neutral.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $511.30 | July 8, 2026 intraday reference used for market cap and valuation math. |
| Immediate support | $508 to $511 | The price was sitting near the 50-day moving average area after the post-deal pullback. |
| Secondary support | $464 to $465 | The 200-day moving average is the larger trend support reference from the Investing.com snapshot. |
| Deep support | $443 to $450 | ChartMill listed a multi-time-frame support zone around $443.74 to $449.52. |
| Near resistance | $514 to $518 | The Fibonacci pivot point near $514.19 and 5-day moving average near $517.67 form the first rebound test. |
| Upper resistance | $529 to $550 | The prior July 2026 highs and the StockAnalysis average analyst target near $550 are the next visible upside references. |
| Moving averages | 5-day near $518, 50-day near $508, 200-day near $464 | Price above the 50-day and 200-day supports the primary trend, while price below the 5-day shows a short-term pause. |
| Momentum | RSI near 45.6 with positive MACD | Momentum is not overbought in the Investing.com daily snapshot, but the pullback means confirmation matters. |
| Volume | 20-day average near 1.87 million shares | Breakouts above the near resistance zone should be judged against above-average volume and deal-related news flow. |
| Volatility | Beta near 0.29, event risk high | StockAnalysis listed low market beta, but biotech-specific FDA, clinical, reimbursement, and M&A events can still move VRTX sharply. |
| Invalidation | Close below $508, then below $464 | A close below the 50-day area weakens the rebound. A break below the 200-day zone would force a broader trend review. |
VRTX AI trading strategy
The VRTX AI trading strategy below is a rules-based research framework, not personal advice. It connects chart levels with CF revenue durability, ALYFTREK uptake, CASGEVY and JOURNAVX adoption, povetacicept progress, Crinetics integration, cash generation, and valuation discipline.
Watch for VRTX to hold the $508 to $511 support area and reclaim the $514 to $518 zone on stronger volume while next company updates confirm 2026 guidance, CF stability, and non-CF launch progress.
A failed rebound followed by a close below the 50-day area should reduce setup confidence, especially if management commentary points to slower non-CF adoption, higher launch spending, or acquisition integration concerns.
If VRTX pulls back toward the $464 to $508 zone without a cut to revenue guidance or a material clinical setback, compare the new price with the verified 30.3x trailing EPS, 35.0x free cash flow, and 10.6x sales references.
Do not treat a lower price as enough if drug pricing pressure, FDA delays, trial failures, or Crinetics deal risk changes the underlying cash-flow outlook.
Track total revenue, CF product revenue, ALYFTREK uptake, CASGEVY infusions, JOURNAVX prescriptions and formulary access, povetacicept milestones, AMKD and diabetes data, Crinetics closing and integration, R&D spend, operating cash flow, share count, and cash plus marketable securities.
Position sizing should reflect that Vertex is financially strong, but still exposed to clinical binary risk, regulatory timing, drug pricing, and large M&A execution.
Investment research summary
Customers and payers fund Vertex because its medicines target serious diseases with clear biology, high unmet need, and in CF, a rare franchise that treats the underlying cause for most eligible patients.
The moat is strongest in CFTR science, patents, clinical and regulatory experience, physician trust, payer access, manufacturing capability, and a pipeline built around causal human biology. It narrows if competitors match efficacy, patents expire, or payers force price concessions.
The thesis fails if CF cash flows fade faster than expected, CASGEVY or JOURNAVX remain niche products, povetacicept or other late-stage programs fail, Crinetics assets miss peak-sales expectations, or the market stops paying a premium for biotech durability.
Reshma Kewalramani has moved Vertex from a CF-centered company toward a multi-franchise rare disease platform. The next test is whether internal pipeline spending and the Crinetics acquisition convert into returns without diluting the quality of the core franchise.
Biotech benefits from genetics, precision medicine, rare disease pricing, gene editing, non-opioid pain innovation, and renal disease research. The countertrend is tougher reimbursement, political scrutiny on drug prices, clinical trial risk, and expensive business development.
VRTX is valued as a durable rare disease leader, not as a distressed biotech. The margin of safety is moderate because the stock already prices in CF durability, non-CF growth, and successful pipeline conversion.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| Current price | $511.30 intraday on July 8, 2026 | StockAnalysis VRTX market cap | July 8, 2026 |
| Market capitalization | $129.77B, verified as $511.30 x 253.81M shares | financial_rigor.py market cap verification | July 8, 2026 |
| Q1 2026 revenue | $2.9869B total revenue, up 8% year over year | Vertex Q1 2026 results | July 8, 2026 |
| Q1 2026 GAAP net income | $1.0314B GAAP net income and $4.02 diluted EPS | Vertex Q1 2026 results | July 8, 2026 |
| Q1 2026 non-GAAP EPS | $4.47 non-GAAP diluted EPS | Vertex Q1 2026 results | July 8, 2026 |
| Cash and marketable securities | About $13.0B at March 31, 2026 | Vertex Q1 2026 results | July 8, 2026 |
| FY2025 revenue | $12.001B, cross-checked with StockAnalysis | Vertex FY2025 results | July 8, 2026 |
| FY2025 GAAP net income | $3.953B, cross-checked with StockAnalysis | Vertex FY2025 results | July 8, 2026 |
| 2026 revenue guidance | $12.95B to $13.1B total revenue | Vertex Q1 2026 results | July 8, 2026 |
| Crinetics acquisition | $85.00 per share cash offer, about $10.0B equity value, expected Q3 2026 close | Vertex Crinetics acquisition announcement | July 8, 2026 |
| Technical moving averages | 5-day $517.67, 50-day $508.31, 200-day $464.37 | Investing.com VRTX technical analysis | July 8, 2026 |
| Valuation math | 30.3x PE, 6.7x PB, 35.0x P/FCF, 10.6x PS, 2.9% FCF yield | financial_rigor.py valuation verification | July 8, 2026 |
This VRTX AI stock analysis is an informational research tool, not investment advice, a recommendation, or a promise of future returns. Forecast scenarios are based on available public data as of July 8, 2026 and may be wrong if revenue, margins, clinical data, FDA decisions, reimbursement policy, Crinetics integration, or market valuation changes.
